CAS NO: | 106266-06-2 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Risperidone is a serotonin5-HT2receptorblocker,P-Glycoproteininhibitor and potentdopamineD2receptorantagonist, withKisof 4.8, 5.9 nM for 5-HT2Aand dopamineD2receptor, respectively. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
体外研究 (In Vitro) | Risperidone is a serotonin 5-HT2receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2Aand dopamine D2receptor, respectively. Risperidone dose-dependently inhibited the release of IL-12 in mature DCs, while the production of IL-10 is dose-dependently increased by Risperidone. A high dose of risperidone can induce TNF-α release from mature DCs[3]. | ||||||||||||||||
体内研究 (In Vivo) | In the first experiment, body weight is found to be slightly but significantly lower in the Risperidone-treated rats as a function of age. Similar to the first experiment, age-dependent differences in body weight are also observed between the three treatment groups in the second locomotor experiment. Rats treated with the 3.0 mg/kg dose of Risperidone weigh less than vehicle-treated rats on postnatal days 35, 38, and 41. The third locomotor experiment involves larger, mixed-sex litters in contrast to the smaller, single-sex litters used in the first two experiments. As noted for the first two experiments, rats treated with Risperidone in the third experiment gain less weight in an age-dependent manner[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 410.48 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C23H27FN4O2 | ||||||||||||||||
CAS 号 | 106266-06-2 | ||||||||||||||||
中文名称 | 利哌酮;利培酮;瑞司哌酮;瑞斯哌东;利哌利酮;利司环酮;利司培酮 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 10 mg/mL(24.36 mM;ultrasonic and warming and heat to 60℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|